drugset / Trial / NCT00133874

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

NCT00133874

Phase 3 Completed 520 enrolled GlaxoSmithKline
RandomizedSingle-groupSingle-blindTreatment

Summary

The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

Timeline

Start
2005-04
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Retapamulin Small molecule 1 % Topical